Contemporary Management of Cardiogenic Shock: A Scientific Statement from the American Heart Association

Authors, Journal, Affiliations, Type, DOI

• van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Kilic A, Menon V, Ohman EM, Sweitzer NK, Thiele H, Washam JB, Cohen MG
• On behalf of the AHA Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission:Lifeline
• Circulation. 2017;136:e232–e268
• Type: AHA Scientific Statement (consensus)
• DOI: 10.1161/CIR.0000000000000525

Overview

This 2017 AHA scientific statement provides the foundational contemporary framework for CS management. It introduces the hemodynamic phenotype classification (cold/wet, cold/dry, warm/wet, normotensive, RV) with registry-derived prevalence estimates and details the CS spiral pathophysiology. It formally proposes the hub-and-spoke regionalized CS center model with a ≥107 cases/year threshold for high-volume benefit, and includes phenotype-specific vasoactive medication guidance. Written before SCAI staging, DanGer Shock, ECLS-SHOCK, CULPRIT-SHOCK final results, and Altshock-2; subsequent ACC 2025 guidance and NEJM 2026 review supersede specific device and trial recommendations, but this statement's pathophysiology and systems-of-care architecture remain foundational.

Keywords

Cardiogenic shock, mechanical circulatory support, hemodynamic phenotypes, vasoactive agents, hub-and-spoke, palliative care, regionalized care, temporary MCS, durable MCS, renal replacement therapy

Key Takeaways

Historical Context

• Killip class IV (CS at presentation) was associated with 81% in-hospital mortality in 1967 (Killip et al.)
• Diamond-Forrester classification (1977): hemodynamic subgroups; "cold and wet" = highest mortality risk
• CS mortality before widespread revascularization: >80%
• SHOCK trial (1999): first landmark RCT demonstrating early revascularization improves survival; no 30-day benefit (46.7% vs 56.0% all-cause mortality; NS) but significant mortality reduction at 6 and 12 months and 6-year follow-up — established early revascularization as standard of care
• IABP: despite decades of widespread use, no survival benefit demonstrated; IABP-SHOCK II confirmed no benefit in AMI-CS at 30 days or 1 year
• CS remains the most common cause of in-hospital death after MI; mortality has declined from >80% to ~50% over the revascularization era

Epidemiology

• CS complicates 5–10% of STEMI and 2–4% of NSTEMI
• Approximately 80,000 CS hospitalizations per year in the United States
• AMI remains the most common cause (~81% of CS presentations at time of publication)
• In-hospital mortality remains 30–50%; long-term mortality remains high even among survivors
• SHOCK trial survivors: 62% alive at 6 years following discharge

Pathophysiology — CS Spiral

• Primary event: ↓myocardial contractility (AMI, HF decompensation, etc.) → ↓CO
• ↓CO → ↓systemic perfusion → metabolic acidosis → further ↓myocardial function
• Compensatory SNS activation: increases heart rate and afterload; initially compensatory but maladaptive at high catecholamine doses (↑myocardial O₂ demand, arrhythmias)
• SIRS/NO-mediated vasodilatation: severe CS triggers systemic inflammatory response with paradoxical vasodilation; exacerbates hypoperfusion despite elevated catecholamines
• Microcirculatory dysfunction: even after restoration of macro-hemodynamics, microcirculatory perfusion may remain impaired — accounts for persistent end-organ dysfunction
• Result: self-perpetuating downward spiral — intervention at any point can break the cycle

Hemodynamic Phenotypes

• "Cold and wet" (classic CS): ↓CO + ↑filling pressures (PCWP >15 mmHg); ~2/3 of CS presentations; most studied phenotype
• "Cold and dry" (euvolemic): ↓CO + normal filling pressures; 28% of CS; associated with RV failure, hypovolemia, or inadequate preload; often underdiagnosed — aggressive fluids may be beneficial
• "Warm and wet" (vasodilatory/SIRS): normal/↑CO + ↑filling pressures; SIRS-mediated vasodilation pattern; vasopressor-predominant treatment
• Normotensive CS: end-organ hypoperfusion without hypotension (SBP ≥90 mmHg); 5.2% of CS; associated with increased mortality if missed; often requires invasive monitoring to diagnose
• RV CS: isolated RV failure (RV infarction, massive PE, decompensated pulmonary HTN); 5.3% of CS; distinct hemodynamic and treatment profile (CVP↑, PCWP normal, CI↓); fluid/vasopressor management differs from LV-dominant CS

Systems of Care — Regionalized Hub-and-Spoke Model

• Hub-and-spoke model proposed as organizational framework for regionalized CS care
• High-volume CS centers (≥107 CS cases/year) associated with improved outcomes in observational data — threshold for "high-volume" benefit
• Proposed CS center criteria: 24/7 cardiac catheterization capability; cardiac surgery; advanced HF/transplant team; full temporary MCS capabilities; ECMO availability
• Mobile ECMO teams as an emerging strategy to support safe interhospital transfer of highest-acuity patients
• Mission:Lifeline expansion to CS: AHA initiative to apply STEMI system-of-care infrastructure to CS triage and transfer
• Regional CS consultation: "Never too early" — contact regional centers at first sign of refractory CS, not after failure of initial therapies

Revascularization

• Early PCI for AMI-CS: strongly recommended; SHOCK trial data at 6/12 months and 6 years drive recommendation despite neutral 30-day endpoint
• At time of publication: CULPRIT-SHOCK trial still enrolling; optimal multivessel vs culprit-only strategy not yet established
• Fibrinolysis: limited role; may be considered when PCI unavailable and transport delay is prolonged, but carries additional risk in CS
• Radial vs femoral access: no RCT-level evidence in CS; femoral often preferred for large-bore access; radial feasible in selected patients

Medical Management — Vasoactive Agents

• Norepinephrine: preferred first-line vasopressor for most hemodynamic phenotypes
• Pure vasopressors (phenylephrine) as first-line: strongly discouraged — reflex bradycardia reduces CO
• Dopamine: substantially more arrhythmic events vs norepinephrine (SOAP II); considered second-line
• Phenotype-specific vasoactive guidance (AHA 2017 Tables 4/5):
  • Cold and wet: norepinephrine + dobutamine; add vasopressin if refractory
  • Cold and dry: inotrope (dobutamine) predominant; cautious vasopressor only if severely hypotensive
  • Warm and wet (vasodilatory): vasopressor (norepinephrine); minimize inotropes; treat underlying SIRS cause
  • RV CS: norepinephrine (RV coronary perfusion) + RV inotrope (dobutamine/milrinone); avoid excessive volume
• β-blockers and RAAS inhibitors: do NOT initiate or continue in active CS; resume only after patient is hemodynamically stable for ≥24 hours off vasopressors/inotropes
• Use lowest effective dose of vasoactive agents for shortest possible duration

Critical Care

• Mechanical ventilation: 78–88% prevalence in CS; positive-pressure ventilation reduces LV afterload; PEEP effects depend on preload status and RV function; no specific mode with evidence in CS
• Care bundles (Table 6): ABCDE bundle (Awakening/Breathing/Coordination/Delirium/Early mobility); ventilator bundle (HOB elevation, oral care, cuff pressure, SBT); central line bundle; stress ulcer prophylaxis; DVT prophylaxis
• Hemodynamic monitoring goals: MAP ≥65 mmHg; CI ≥2.2 L/min/m² (Table 3 provides phenotype-specific targets)

Renal Replacement Therapy

• AKI prevalence in CS: 13–28% of patients
• ~20% of CS patients require RRT during hospitalization
• KDIGO Stage 2 AKI (creatinine ≥2× baseline or UO <0.5 mL/kg/h for ≥12 h) used as threshold for CRRT initiation in CS
• Continuous renal replacement therapy (CRRT) preferred over intermittent hemodialysis in hemodynamically unstable CS — better hemodynamic tolerance, avoidance of fluid shifts
• Early CRRT initiation (before conventional indications reached): no outcome benefit established

Temporary MCS

• IABP: most widely used MCS device in CS at time of publication despite IABP-SHOCK II negative result; retained role in mechanical complications (acute MR, VSD) and when percutaneous MCS unavailable
• Post-IABP-SHOCK II: downgraded from Class I to Class IIIa recommendation for routine use in European revascularization and NSTEMI-ACS guidelines
• Percutaneous MCS (Impella 2.5/CP/5.0; TandemHeart): 2009 meta-analysis (3 RCTs): higher CI and MAP, more bleeding, no mortality difference vs IABP; Impella CP vs IABP pilot (n=48): no mortality difference
• VA-ECMO: no randomized trials available at time of publication; ELSO registry: 56% survived to decannulation; 41% survived to discharge; retrograde aortic flow → ↑LV afterload; LV venting (IABP + VA-ECMO, or Impella + VA-ECMO, or atrial septostomy) recommended in inadequate LV unloading
• VA-ECMO relative contraindications: age >75 years; life expectancy <1 year; severe PVD; advanced liver disease; contraindication to anticoagulation; neurological injury
• RV support — Impella RP: intracardiac pump from IVC to pulmonary artery; approved via humanitarian device exemption based on RECOVER RIGHT multicenter study
• CentriMag: biventricular surgical support device; up to 10 L/min; magnetically levitated; no RCTs; sternotomy required; both LVAD and RVAD configurations

Durable MCS

• HeartMate II + HeartWare HVAD: >95% of US FDA-approved durable MCS implants at time of publication
• INTERMACS profile 1 (CS) implants declined from 40% (2006) to 12% (2010) — reflecting recognition that implantation in active shock carries excessive perioperative mortality (38% 30-day mortality in profile 1–2)
• Bridge-to-bridge strategy: temporary MCS stabilization → durable LVAD implant when hemodynamics improved; becoming increasingly commonplace; supported by practice guidelines
• Durable MCS appropriate in CS when: myocardial recovery unlikely without long-term support + meaningful functional recovery expected + no irreversible end-organ dysfunction + no systemic infection + no durable MCS contraindication

Heart Transplantation

• 44% of MCS device implants in INTERMACS profile 1–2 patients performed with BTT strategy
• ECMO before transplantation: low rates (1.1% of transplants, 2006–2012); use of LVAD before transplant increasing as alternative bridge strategy
• Concurrent transplant evaluation recommended in all patients being assessed for durable MCS

Palliative Care

• Only 6–8% of advanced HF patients referred for palliative care during hospitalization; ACS palliative care use declined from 6% (1997) to 2% (2013)
• CS-specific challenges: acute presentation limits time for advance care discussions; lack of validated CS prognostic tools; patients may transiently improve after MCS/revascularization, creating false hope
• Recommendation: include palliative care physician in multidisciplinary CS team regardless of MCS candidacy, given perioperative mortality risk
• Curative and palliative care should run concurrently, not sequentially
• Key domains (Table 7): consultation services, CS-specific preparedness plan, withdrawal of life-sustaining measures protocol, physical symptom management, emotional/spiritual support

Limitations of the Document

• Pre-publication of SCAI shock staging (2019), DanGer Shock, ECLS-SHOCK, CULPRIT-SHOCK final results, Altshock-2, 4-trial VA-ECMO IPD meta-analysis — specific device recommendations and evidence base substantially updated by subsequent literature
• No randomized trial evidence for many recommendations; mostly expert consensus and observational registry data
• MCS device evidence at time of publication was limited to small trials and registry studies — notably, no positive RCT evidence existed for any percutaneous MCS device
• Primarily AMI-CS focused; HF-CS, postcardiotomy CS, and secondary CS less thoroughly addressed
• Palliative care section largely extrapolated from advanced HF and cancer literature; limited CS-specific evidence base

Key Concepts Mentioned

• concepts/Cardiogenic-Shock — central subject; hemodynamic phenotypes, CS spiral, epidemiology, management
• concepts/Temporary-Mechanical-Circulatory-Support — IABP, Impella, VA-ECMO, CentriMag, Impella RP, durable MCS, bridge-to-bridge
• concepts/SCAI-Shock-Classification — staging system that subsequently formalized the phenotype categories introduced in this statement

Key Entities Mentioned

• SHOCK trial — landmark revascularization RCT; historical foundation
• IABP-SHOCK II — established IABP's lack of survival benefit in AMI-CS
• ELSO Registry — VA-ECMO survival data (56% decannulation; 41% discharge)
• RECOVER RIGHT — Impella RP humanitarian device exemption basis
• INTERMACS — registry tracking durable MCS outcomes; profile 1–2 data
• Mission:Lifeline (AHA) — STEMI infrastructure proposed for CS extension

Wiki Pages Updated

• wiki/sources/cardiogenic-shock-aha-2017.md (created)
• wiki/concepts/Cardiogenic-Shock.md (updated — source_count 2→3)
• wiki/concepts/Temporary-Mechanical-Circulatory-Support.md (updated — source_count 2→3)
• wiki/sourceindex.md (updated)
• wiki/wikiindex.md (no new concept rows; all CS concepts already indexed)
• log.md (updated)